Sign in
Taking people in United StatesNo phase

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Key facts

Who runs it
BeiGene
Where
Duarte, Glendale, Hattiesburg, Huntsville, Las Vegas, Mobile, and Rancho Mirage, United StatesSee the 7 sitesAlso in 1 other country, 1 site
Trial code
Status
Recruiting
People taking part
111 people, planned
Started
3 Mar 2023
Expected to end
Dec 2027
Type of study
Observational, 2 groups
Treatments tested
  • Zanubrutinib
Record updated
7 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Clinical and definitive histologic diagnosis of WM
  • Measurable disease, as defined by a serum immunoglobulin M (IgM) level > 0.5 g/dL at the time of zanubrutinib initiation
  • Started treatment with zanubrutinib, has been treated with zanubrutinib, or is planned to be prescribed zanubrutinib for the treatment of WM
  • Bone marrow specimens with central MYD88 test results of:; Cohort 1: MYD88 L265P mutation; enrollment of TN participants will be stopped in each racial and ethnic participant group when the required numbers of participants in the group are met; Cohort 2: non-L265P MYD88 mutation(s) and MYD88WT

Who cannot take part

  • Prior or concurrent active malignancy ≤ 2 years before the first dose of zanubrutinib, except for malignancies that, in the investigator's opinion, will not obscure the interpretation of safety or efficacy results
  • Concurrent participation in another therapeutic clinical study while receiving zanubrutinib, although the participant may be eligible depending on the status of the interventional study after discussion with the Medical Monitor or designee on an individual basis
  • Evidence of disease transformation before the first dose of zanubrutinib
  • Evidence of other non-Hodgkin Lymphoma (NHL) subtypes

Where in United States

Also in 1 other country, 1 site

  • City of Hope National Medical CenterDuarte, United StatesContact: Study DirectorTaking people
  • Los Angeles Cancer Network (LACN)Glendale, United StatesContact: Study DirectorTaking people
  • Hattiesburg Hematology and Oncology ClinicHattiesburg, United StatesContact: Study DirectorNo longer taking part
  • Clearview Cancer InstituteHuntsville, United StatesContact: Study DirectorTaking people
  • Comprehensive Cancer Centers of NevadaLas Vegas, United StatesContact: Study DirectorTaking people
  • South Alabama Medical Science Foundation Mitchell Cancer InstituteMobile, United StatesContact: Study DirectorTaking people
  • Eisenhower Medical Center, Lucy Curci Cancer CenterRancho Mirage, United StatesContact: Study DirectorTaking people

About the trial

What the trial wants to find out

This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.

The 2 groups in the trial

  • Cohort 1: MYD88 L265P mutation

    Arm A: Treatment-naïve (TN); Arm B: Relapsed/refractory (R/R)

    Treatment: Zanubrutinib

  • Cohort 2: Non-L265P MYD88 mutation(s) and MYD88 wildtype

    Arm C: TN and R/R

    Treatment: Zanubrutinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia
Record updated
7 August 2026